Abera Bioscience

Abera Bioscience Receivables

Accounts Receivable of Abera Bioscience (ABERA.SL) as of Nov 18, 2026.

Receivables

-SEK

Last updated:

Accounts Receivable of Abera Bioscience is 2026 - SEK. Accounts Receivable of Abera Bioscience was 2025 - SEK. It decreases by % lower compared to the previous year.

The Abera Bioscience Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
0.00 SEK
Jan 1, 2019
0.00 SEK
Jan 1, 2020
0.00 SEK
Jan 1, 2021
0.00 SEK
Jan 1, 2022
0.00 SEK
Jan 1, 2023
0.00 SEK
Jan 1, 2024
0.00 SEK
Jan 1, 2025
0.00 SEK
The Abera Bioscience Receivables history
YEARReceivablesYoY
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB develops pharmaceutical products through research and development, focusing on vaccine candidates using its delivery platform. The company aims to advance these candidates to late pre-clinical or early clinical stages before seeking licensing partners for further development. Its technology targets pneumococci and immunooncology, with operations centered in the Nordic market. The business model relies on securing partnerships for vaccine development rather than direct sales, leveraging its platform to attract collaborators in the medical and microbiological sectors. The company's revenue stream comes from licensing agreements with partners who take over further development and commercialization of the vaccine candidates. Abera Bioscience does not sell products directly but instead generates income through these partnerships, which align with its focus on late pre-clinical and early clinical phases. The Nordic market serves as the primary operational region, where the company collaborates with entities in the medical, molecular, and microbiological fields to advance vaccine research. Abera Bioscience AB's business strategy emphasizes platform-based vaccine development, targeting pneumococci and immunooncology areas. The company seeks to transition its vaccine candidates to partners who can handle later-stage development, ensuring the platform's value is realized through collaborative agreements. This approach allows Abera to focus on R&D while partners manage clinical trials and market entry, creating a sustainable revenue model without direct product sales. Abera Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abera Bioscience stock

On Eulerpool you can find the complete historical development of Accounts Receivable Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Abera Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Abera Bioscience

All Key Metrics — Abera Bioscience